Abegão Pinto Luís, Vandewalle Evelien, Gerlier Laetitia, Stalmans Ingeborg
Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium.
Ophthalmologica. 2014;231(3):166-71. doi: 10.1159/000356468. Epub 2013 Dec 21.
To assess a change in visual-related quality of life (QoL) in glaucoma patients after switching from preservative-containing medical therapy to preservative-free unit dose timolol/dorzolamide fixed combination (TDFC UD).
Prospective, noninterventional, multicenter 8-week study. Primary outcome was a change in visual symptoms at week 8, as assessed by the Glaucoma Symptom Scale (GSS).
80 patients completed the study. There was a clinically significant increase in the scores of all GSS-related categories at week 8 when compared to baseline (GSS symptom week 8: +21.15 ± 37.9%, GSS function week 8: +10.3 ± 31.6%, both p < 0.001 vs. baseline). Comparison between patients taking only TDFC UD and patients taking TDFC UD plus concomitant medications did not detect differences in any GSS category (p > 0.50 in all comparisons).
Switching to TDFC UD significantly improved the self-reported QoL of glaucoma patients. This can be seen even in patients who are taking concomitant ocular treatments.
评估青光眼患者从含防腐剂的药物治疗转换为不含防腐剂的单位剂量噻吗洛尔/多佐胺固定复方制剂（TDFC UD）后视觉相关生活质量（QoL）的变化。
前瞻性、非干预性、多中心8周研究。主要结局是第8周时视觉症状的变化，通过青光眼症状量表（GSS）进行评估。
80例患者完成研究。与基线相比，第8周时所有GSS相关类别的得分均有临床显著增加（第8周GSS症状：+21.15±37.9%，第8周GSS功能：+10.3±31.6%，两者与基线相比p<0.001）。仅服用TDFC UD的患者与服用TDFC UD加用其他药物的患者之间的比较未发现任何GSS类别存在差异（所有比较中p>0.50）。
转换为TDFC UD可显著改善青光眼患者自我报告的生活质量。即使在接受其他眼部治疗的患者中也可见到这一情况。
